Name | Glycyl-L-α-glutamyl-4-carboxy-L-α-glutamyl-4-carboxy-L-α-glutamyl-L-valyl-L-alanyl-L-lysyl-L-methionyl-L-alanyl-L-alanyl-4-carboxy-L-α-glutamyl-L-leucyl-L-alanyl-L-arginyl-4-carboxy-L-α-glutamyl-L-asparaginyl-L-isoleucyl-L-alanyl-L-lysyl-N-[(4R,7S,10S,13S,16R)-13-(4-aminobutyl)-7-(2-amino-2-oxoethyl)-4-{[(2S)-1-[(2S)-2-carboxy-1-pyrrolidinyl]-3-(4-hydroxyphenyl)-1-oxo-2-propanyl]carbamoyl}-10-isopropyl-6,9,12,15-tetraoxo |
---|---|
Synonyms |
Glycinamide, glycyl-L-α-glutamyl-4-carboxy-L-α-glutamyl-4-carboxy-L-α-glutamyl-L-valyl-L-alanyl-L-lysyl-L-methionyl-L-alanyl-L-alanyl-4-carboxy-L-α-glutamyl-L-leucyl-L-alanyl-L-arginyl 
-4-carboxy-L-α-glutamyl-L-asparaginyl-L-isoleucyl-L-alanyl-L-lysyl-N-[(4R,7S,10S,13S,16R)-13-(4-aminobutyl)-7-(2-amino-2-oxoethyl)-4-[[[(1S)-2-[(2S)-2-carboxy-1-pyrrolidinyl]-1-[(4-hydroxyphenyl)m ;ethyl]-2-oxoethyl]amino]carbonyl]-10-(1-meth
Glycyl-L-α-glutamyl-4-carboxy-L-α-glutamyl-4-carboxy-L-α-glutamyl-L-valyl-L-alanyl-L-lysyl-L-methionyl-L-alanyl-L-alanyl-4-carboxy-L-α-glutamyl-L-leucyl-L-alanyl-L-arginyl-4-carboxy-L- 
α-glutamyl-L-asparaginyl-L-isoleucyl-L-alanyl-L-lysyl-N-[(4R,7S,10S,13S,16R)-13-(4-aminobutyl)-7-(2-amino-2-oxoethyl)-4-{[(2S)-1-[(2S)-2-carboxy-1-pyrrolidinyl]-3-(4-hydroxyphenyl)-1-oxo-2-propany ;l]carbamoyl}-10-isopropyl-6,9,12,15-tetraoxo |
Description | Conantokin R (Con-R) is an NMDA receptor peptide antagonist with an IC50 of 93 nM. Conantokin R binds Zn2+ and Mg2+ with Kds of 0.15 μM and 6.5 μM, respectively. Conantokin R shows anticonvulsant activity[1][2]. |
---|---|
Related Catalog | |
Target |
IC50: 93 nM (NMDA receptor)[1] |
References |
Density | 1.6±0.1 g/cm3 |
---|---|
Molecular Formula | C127H201N35O49S3 |
Molecular Weight | 3098.35 |
Exact Mass | 3096.347412 |
LogP | -8.16 |
Index of Refraction | 1.675 |